Kranzler Elissa C, Olson Julie S, Nichols Helen M, Yuen Eva Yn, McManus Shauna, Buzaglo Joanne S, Zaleta Alexandra K
Cancer Support Community, Research and Training Institute, Philadelphia, PA, USA.
Cancer Support Community, Washington, DC, USA.
J Patient Exp. 2021 Aug 25;8:23743735211034967. doi: 10.1177/23743735211034967. eCollection 2021.
Chronic lymphocytic leukemia (CLL) often requires consideration of multiple treatment options. Shared decision-making (SDM) is important, given the availability of increasingly novel therapies; however, patient-provider treatment conversations vary. We examined relationships between patient-provider discussions of new CLL treatment options and sociodemographic, clinical, and patient-provider communication variables among 187 CLL patients enrolled in Cancer Support Community's Cancer Experience Registry. Factors significantly associated with self-reports of whether patients' providers discussed new CLL treatment options with them were examined using χ tests, tests, and hierarchical logistic regression. Fifty-eight percent of patients reported discussing new treatment options with their doctor. Patients with higher education were 3 times more likely to discuss new treatment options relative to those with lower education (OR = 3.06, < .05). Patients who experienced a cancer recurrence were 7 times more likely to discuss new treatment options compared to those who had not (OR = 7.01, < .05). Findings offer insights into the correlates of patient-provider discussions of new CLL treatment options. As novel therapies are incorporated into standards of care, opportunities exist for providers to improve patient care through enhanced SDM.
慢性淋巴细胞白血病（CLL）通常需要考虑多种治疗方案。鉴于越来越多新疗法的出现，共同决策（SDM）很重要；然而，医患之间关于治疗的对话存在差异。我们在癌症支持社区癌症经验登记处登记的187例CLL患者中，研究了医患关于新的CLL治疗方案的讨论与社会人口统计学、临床以及医患沟通变量之间的关系。使用χ检验、检验和分层逻辑回归分析了与患者关于其医生是否与他们讨论新的CLL治疗方案的自我报告显著相关的因素。58%的患者报告与医生讨论了新的治疗方案。与低学历患者相比，高学历患者讨论新治疗方案的可能性高出3倍（OR = 3.06，< .05）。与未经历癌症复发的患者相比，经历癌症复发的患者讨论新治疗方案的可能性高出7倍（OR = 7.01，< .05）。研究结果为医患关于新的CLL治疗方案讨论的相关因素提供了见解。随着新疗法被纳入护理标准，医疗服务提供者有机会通过加强共同决策来改善患者护理。
